Margaret McGlynn - Vertex Pharmaceuticals Independent Director

VRTX Stock  MXN 9,266  148.99  1.63%   

Director

Ms. Margaret G. McGlynn is Independent Director of Vertex Pharmaceuticals Incorporated. Ms. McGlynn retired from Merck Co. in 2009, where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products. During her 26 year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global notforprofit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn serves as a member of the Board of Directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, and Amicus Therapeutics, Inc., a biopharmaceutical company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences since 2011.
Age 59
Tenure 13 years
Professional MarksMBA
Phone617 341 6100
Webhttps://www.vrtx.com
McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo.

Margaret McGlynn Latest Insider Activity

Tracking and analyzing the buying and selling activities of Margaret McGlynn against Vertex Pharmaceuticals stock is an integral part of due diligence when investing in Vertex Pharmaceuticals. Margaret McGlynn insider activity provides valuable insight into whether Vertex Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Vertex Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Vertex Pharmaceuticals has accumulated 893.85 M in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.52, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vertex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

DIRECTOR Age

Robert BaileyMicron Technology
61
Richard BeyerMicron Technology
71
Patrick ByrneMicron Technology
57
Lynn DugleMicron Technology
60
Steven GomoMicron Technology
67
Mary McCarthyMicron Technology
64
Richard GalantiCostco Wholesale
67
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMACEUTICAL operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 3400 people. Vertex Pharmaceuticals (VRTX) is traded on Mexican Exchange in Mexico and employs 4,800 people.

Management Performance

Vertex Pharmaceuticals Leadership Team

Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President, Chief Legal and Administrative Officer
Alan Garber, Independent Director
Mike Tirozzi, SVP Officer
Damian Esq, Chief VP
Jeffrey MD, Ex Chairman
MD FASN, Pres CEO
Stuart BSc, Ex COO
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Diana McKenzie, Independent Director
Sangeeta Bhatia, Independent Director
Terrence Kearney, Independent Director
Nia Tatsis, Senior Vice President Chief Regulatory Officer
Kristen Ambrose, Tax, Accounting
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer
Amit Sachdev, Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Charles Wagner, Chief Financial Officer, Executive Vice President
Gerald Bruce, Executive Vice President Commercial Operations
Ourania Tatsis, Ex Officer
Bruce Sachs, Co-Lead Independent Director
Susie Lisa, VP Relations
Lloyd Carney, Independent Director
Yuchun Lee, Independent Director
Stuart Arbuckle, Executive Vice President Chief Commercial Officer
Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Jeffrey Leiden, Chairman of the Board, President, Chief Executive Officer

Vertex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.